Study identifier:BN-00S-0022
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A randomized double blind comparison between single doses of Symbicort Turbuhaler (budesonide/formoterol combination), formoterol, salbutamol and placebo in repeated AMP-challenges in patients with mild - to moderate asthma. Investigating the supplementary value of the budesonide component within Symbicort when tested in a model of slow onset acute asthma
asthma
Phase 4
No
budesonide/formoterol Turbuhaler, formoterol Turbuhaler, salbutamol
All
20
Interventional
18 Years - 55 Years
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
The aim is to study whether the budesonide component within the budesonide/ formoterol combination inhaler has additive value in a model of “slow onset acute asthma” , namely three AMP provocation tests performed on one day
Location
Location
Groningen, Netherlands
Location
Amsterdam, Netherlands
Arms | Assigned Interventions |
---|
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.